NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) announced today that its scientific collaborators will present data from a research study identifying a possible biomarker for the diagnosis of NASH, or non-alcoholic steatohepatitis. The presentation will take place on November 5th at the American Association for the Study of Liver Diseases meeting (AASLD) in Boston.
